Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Thursday, 27 December 2012
CytImmune and AstraZeneca to Research Potential New Nanomedicine Rockville, MD and Waltham, MA –December 27, 2012-CytImmune and AstraZeneca have entered into an agreement to study the feasibility of a new cancer nanomedicine that will bind an oncology compound from AstraZeneca to CytImmune’s CYT-6091 nanomedicine platform.
Thursday, 20 December 2012
AstraZeneca and LegoChem Biosciences announce collaboration on treatment of antibiotic-resistant bacterial infections AstraZeneca has entered into a research and development option & license agreement with LegoChem Biosciences to develop a novel antibiotic to treat drug-resistant bacterial infections.
Tuesday, 18 December 2012
AstraZeneca and Fudan University sign research collaboration in China AstraZeneca today announced the signing of a research collaboration with Fudan University, one of China’s leading academic institutions in the area of cardiovascular diseases (CVDs), a leading cause of death in China and worldwide.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar